X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3138) 3138
Publication (279) 279
Newsletter (238) 238
Newspaper Article (56) 56
Book Review (26) 26
Book Chapter (10) 10
Magazine Article (9) 9
Dissertation (6) 6
Conference Proceeding (4) 4
Data Set (4) 4
Trade Publication Article (2) 2
Transcript (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pemetrexed (2910) 2910
humans (2039) 2039
oncology (1534) 1534
guanine - analogs & derivatives (1378) 1378
index medicus (1359) 1359
chemotherapy (1323) 1323
female (1102) 1102
lung neoplasms - drug therapy (1098) 1098
male (1075) 1075
middle aged (959) 959
aged (927) 927
cancer (893) 893
antineoplastic combined chemotherapy protocols - therapeutic use (882) 882
carcinoma, non-small-cell lung - drug therapy (863) 863
glutamates - administration & dosage (751) 751
guanine - administration & dosage (751) 751
cisplatin (657) 657
adult (641) 641
lung neoplasms - pathology (618) 618
treatment outcome (578) 578
lung cancer, non-small cell (571) 571
lung cancer (557) 557
glutamates - therapeutic use (514) 514
guanine - therapeutic use (514) 514
care and treatment (498) 498
carboplatin (496) 496
antineoplastic agents - therapeutic use (427) 427
carcinoma, non-small-cell lung - pathology (427) 427
cisplatin - administration & dosage (425) 425
gemcitabine (407) 407
research (402) 402
respiratory system (388) 388
neoplasm staging (379) 379
non-small cell lung cancer (370) 370
aged, 80 and over (350) 350
glutamates - adverse effects (342) 342
guanine - adverse effects (342) 342
mesothelioma (341) 341
mesothelioma - drug therapy (336) 336
pharmacology & pharmacy (312) 312
prognosis (304) 304
disease-free survival (303) 303
docetaxel (294) 294
antineoplastic combined chemotherapy protocols - adverse effects (283) 283
thymidylate synthase (278) 278
lung neoplasms - mortality (275) 275
hematology, oncology and palliative medicine (274) 274
deoxycytidine - analogs & derivatives (270) 270
bevacizumab (267) 267
drug therapy (263) 263
pemetrexed - administration & dosage (259) 259
cell lung-cancer (258) 258
trial (258) 258
therapy (254) 254
malignant pleural mesothelioma (253) 253
cancer therapies (251) 251
metastasis (249) 249
antineoplastic agents (248) 248
erlotinib (240) 240
phase-iii (235) 235
antimitotic agents (234) 234
carcinoma, non-small-cell lung - mortality (234) 234
adenocarcinoma - drug therapy (232) 232
carboplatin - administration & dosage (231) 231
glutamates - pharmacology (231) 231
guanine - pharmacology (231) 231
survival rate (228) 228
pleural neoplasms - drug therapy (225) 225
survival (221) 221
retrospective studies (220) 220
combination (218) 218
analysis (210) 210
lung neoplasms - genetics (210) 210
phase-iii trial (204) 204
animals (202) 202
deoxycytidine - administration & dosage (202) 202
antimetabolites, antineoplastic - therapeutic use (198) 198
cell line, tumor (197) 197
gefitinib (197) 197
nsclc (195) 195
health aspects (192) 192
pulmonary/respiratory (189) 189
mutation (188) 188
clinical trials (185) 185
lung cancer, small cell (185) 185
tumors (185) 185
medicine & public health (184) 184
adenocarcinoma (180) 180
survival analysis (176) 176
phase-ii trial (175) 175
mesothelioma - pathology (172) 172
multitargeted antifolate (171) 171
oncology, experimental (171) 171
patients (171) 171
antineoplastic agents - adverse effects (164) 164
carcinoma, non-small-cell lung - genetics (156) 156
paclitaxel (156) 156
follow-up studies (152) 152
pemetrexed - therapeutic use (152) 152
drug administration schedule (149) 149
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3166) 3166
French (96) 96
Japanese (64) 64
Chinese (45) 45
German (18) 18
Spanish (17) 17
Korean (14) 14
Italian (8) 8
Portuguese (7) 7
Czech (5) 5
Polish (5) 5
Hungarian (3) 3
Russian (2) 2
Danish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 02/2017, Volume 376, Issue 7, pp. 629 - 640
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 12/2017, Volume 142, pp. 266 - 270
Journal Article
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, ISSN 1556-0864, 8/2017, Volume 12, Issue 8, pp. 1299 - 1308
Journal Article
Journal Article
Lung Cancer, ISSN 0169-5002, 2015, Volume 89, Issue 2, pp. 154 - 160
Journal Article
Lung Cancer, ISSN 0169-5002, 2015, Volume 88, Issue 3, pp. 319 - 324
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 10, pp. 2443 - 2450
Background: Icotinib has been previously shown to be non-inferior to gefitinib in non-selected advanced non-small-cell lung cancer patients when given as... 
Icotinib | First-line | EGFR mutation-positive | NSCLC | Cisplatin/pemetrexed plus pemetrexed maintenance | GEFITINIB | MULTICENTER | CTONG-0802 | CANCER | CHEMOTHERAPY | TRIAL | cisplatin/pemetrexed plus pemetrexed maintenance | CISPLATIN | ONCOLOGY | first-line | DOUBLE-BLIND | ERLOTINIB | icotinib | Index Medicus
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 11/2019, Volume 863, p. 172665
Glioma is one of the most lethal malignancies and molecular regulators driving gliomagenesis are incompletely understood. Although temozolomide (TMZ) has been... 
DHFR | Temozolomide | Glioma | TYMS | AMPK-mTOR | Pemetrexed
Journal Article
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, ISSN 0031-6903, 09/2017, Volume 137, Issue 9, pp. 1087 - 1094
An ethoxycarbonyl 1-ethyl hemiacetal ester of levofloxacin (LVFX-EHE) avoids insoluble chelate formation with metal-containing drugs in the intestinal tract... 
pemetrexed dimedoxomil | prodrug of levofloxacin | levofloxacin | prodrug of pemetrexed | hemiacetal prodrug | PHARMACOLOGY & PHARMACY | oral pemetrexed
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article
Journal Article